Nutritional and Contractile Regulation of Muscle Growth
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Muscle wasting, which involves the loss of muscle tissue, is common in many conditions, such as cancer, AIDS, trauma, kidney failure, bone fracture, and sepsis. It is also prevalent among the elderly and in people who experience periods of physical inactivity and weightlessness. Muscle wasting can lead to overall weakness, immobility, physical dependence, and a greater risk of death when exposed to infection, surgery, or trauma. There is a need to develop scientifically based treatments that prevent muscle wasting. As one step towards such a goal, this study will examine the physiological and cellular mechanisms that regulate skeletal muscle growth.
| Condition | Intervention |
|---|---|
|
Sarcopenia |
Drug: Rapamycin Other: Amino acid supplementation Other: Low-intensity resistance exercise Drug: Sodium nitroprusside Device: Blood flow restriction cuff |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Factorial Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Basic Science |
| Official Title: | Nutritional and Contractile Regulation of Muscle Growth (Cycle 2) |
- Muscle protein synthesis [ Time Frame: Measured during the 8-hour infusion study ] [ Designated as safety issue: No ]
- Phosphorylation status of mTOR signaling proteins [ Time Frame: Measured during the 8-hour infusion study ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 144 |
| Study Start Date: | April 2009 |
| Estimated Study Completion Date: | September 2013 |
| Estimated Primary Completion Date: | September 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: Exp 1: AA + Rap
Participants will receive amino acid supplementation and rapamycin.
|
Drug: Rapamycin
Single 16-mg oral dose
Other: Amino acid supplementation
Nutritional drink containing essential amino acids
|
|
Placebo Comparator: Exp 1: AA
Participants will receive amino acid supplementation and placebo rapamycin.
|
Other: Amino acid supplementation
Nutritional drink containing essential amino acids
|
|
Active Comparator: Exp 1: HEx + Rap
Participants will receive rapamycin and placebo amino acid supplementation, and they will undergo high-intensity resistance exercise.
|
Drug: Rapamycin
Single 16-mg oral dose
Other: Low-intensity resistance exercise
Leg extension exercises on a Cybex leg extension machine
|
|
Placebo Comparator: Exp 1: HEx
Participants will receive placebo amino acid supplementation and placebo rapamycin, and they will undergo high-intensity resistance exercise.
|
Other: Low-intensity resistance exercise
Leg extension exercises on a Cybex leg extension machine
|
|
Active Comparator: Exp 1: HEx + AA + Rap
Participants will receive amino acid supplementation and rapamycin, and they will undergo high-intensity resistance exercise.
|
Drug: Rapamycin
Single 16-mg oral dose
Other: Amino acid supplementation
Nutritional drink containing essential amino acids
Other: Low-intensity resistance exercise
Leg extension exercises on a Cybex leg extension machine
|
|
Placebo Comparator: Exp 1: HEx + AA
Participants will receive amino acid supplementation and placebo rapamycin, and they will undergo high-intensity resistance exercise.
|
Other: Amino acid supplementation
Nutritional drink containing essential amino acids
Other: Low-intensity resistance exercise
Leg extension exercises on a Cybex leg extension machine
|
|
Active Comparator: Exp 2: LExFR + Rap
Participants will receive rapamycin and will undergo low-intensity resistance exercise with blood flow restriction.
|
Drug: Rapamycin
Single 16-mg oral dose
Device: Blood flow restriction cuff
Blood flow restriction for 5 minutes after the second biopsy
Other Name: KAATSU cuff
Other: Low-intensity resistance exercise
Leg extension exercises on a Cybex leg extension machine
|
|
Placebo Comparator: Exp 2 and 3: LExFR
Participants will receive placebo rapamycin and will undergo low-intensity resistance exercise with blood flow restriction.
|
Device: Blood flow restriction cuff
Blood flow restriction for 5 minutes after the second biopsy
Other Name: KAATSU cuff
Other: Low-intensity resistance exercise
Leg extension exercises on a Cybex leg extension machine
|
|
Active Comparator: Exp 2: SNP
Participants will receive sodium nitroprusside in a resting state.
|
Drug: Sodium nitroprusside
Variable rate for 3 hours
|
|
Active Comparator: Exp 2: FR
Participants will undergo blood flow restriction in a resting state.
|
Device: Blood flow restriction cuff
Blood flow restriction for 5 minutes after the second biopsy
Other Name: KAATSU cuff
|
|
Active Comparator: Exp 2: LEx + SNP
Participants will receive sodium nitroprusside and undergo low-intensity resistance exercise.
|
Drug: Sodium nitroprusside
Variable rate for 3 hours
Other: Low-intensity resistance exercise
Leg extension exercises on a Cybex leg extension machine
|
|
Placebo Comparator: Exp 3: LEx
Participants will undergo low-intensity resistance exercise.
|
Other: Low-intensity resistance exercise
Leg extension exercises on a Cybex leg extension machine
|
|
Active Comparator: Exp 3: HEx
Participants will undergo high-intensity resistance exercise.
|
Other: Low-intensity resistance exercise
Leg extension exercises on a Cybex leg extension machine
|
|
Active Comparator: Exp 3: HEx + AA
Participants will receive amino acid supplementation and will undergo high-intensity resistance exercise.
|
Other: Low-intensity resistance exercise
Leg extension exercises on a Cybex leg extension machine
|
Detailed Description:
Skeletal muscle comprises about 40% of one's body weight and contains about 50% to 75% of all the proteins in the human body. The turnover of protein is a regular process in the human body. In healthy adults, the interplay between muscle protein synthesis and muscle protein breakdown results in no net growth or loss of muscle mass. But when the scale tips towards muscle protein breakdown, muscle wasting can occur. This can result in negative consequences, because not only does muscle fill the obvious role of converting chemical energy into mechanical energy for moving and maintaining posture, but muscle is also involved in the following less apparent roles: regulating metabolism; removing potentially toxic substances from blood circulation; producing fuel for other tissues; storing energy and nitrogen, both of which are important for fueling the brain and immune system; and facilitating wound healing during malnutrition, starvation, injury, and disease. Therefore, muscle is important not only for physical independence but also for mere survival of the human body. In fact, a mere 30% loss of the body's proteins results in impaired respiration and circulation and can eventually lead to death. The purpose of this study is to examine the physiological and cellular mechanisms that regulate skeletal muscle growth. Results from the study may help to develop future treatments for maintaining and possibly increasing muscle mass as a way to improve function, reduce disease complications, and increase survival.
This study will enroll healthy participants who will be randomly assigned to one of several treatment arms within one of three separate experiments. Overall, the three experiments will examine the following: (1) whether the mammalian target of rapamycin (mTOR) signaling pathway--a group of molecules that work together to control a specific cellular function--is responsible for stimulating muscle protein synthesis after resistance exercise and/or ingestion of an amino acid supplement; (2) whether restricting blood flow with a blood pressure cuff during low-intensity resistance exercise ultimately leads to muscle protein synthesis; and (3) whether aging is associated with reduced physiological and cellular mechanisms that are related to muscle protein synthesis and whether such a reduction can be overcome by post-exercise ingestion of an amino acid supplement or blood flow restriction during low-intensity resistance exercise.
Depending on which treatment arm participants are assigned to, they may receive amino acid supplementation, the drug rapamycin, the drug sodium nitroprusside, and/or placebo. They may also undergo high-intensity resistance exercise, low-intensity resistance exercise, or low-intensity resistance exercise along with blood flow restriction. All participants will attend a single 8-hour study visit and a follow-up visit 1 week later. During the study visit, participants will undergo the following: measurements of vital signs, height, and weight; blood and urine sampling; a dual energy x-ray absorptiometry (DEXA) scan; and an infusion study that will include additional blood sampling, muscle biopsies, and assigned interventions. The follow-up visit will include evaluation of any incisions that were made during the infusion study.
Eligibility| Ages Eligible for Study: | 18 Years to 85 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- 18 to 35 years of age for the young groups
- 60 to 85 years of age for the older groups
- In the follicular phase for the young women participants
- Ability to sign consent form, as based on a score of greater than 25 on the 30-item Mini Mental State Examination (MMSE)
- Stable body weight for at least 1 year
Exclusion Criteria:
- Physical dependence or frailty, as determined by impairment in any of the activities of daily living (ADLs), history of more than two falls per year, or significant weight loss in the past year
- Exercise training that consists of more than two weekly sessions of moderate to high intensity aerobic or resistance exercise
- Significant heart, liver, kidney, blood, or respiratory disease
- Peripheral vascular disease
- Diabetes mellitus or other untreated endocrine disease
- Active cancer
- History of cancer for participants who may be randomly assigned to rapamycin)
- Acute infectious disease or history of chronic infections (e.g., tuberculosis, hepatitis, HIV, herpes)
- Treatment with anabolic steroids or corticosteroids within 6 months of study entry
- Alcohol or drug abuse
- Tobacco use (smoking or chewing)
- Malnutrition (e.g., body mass index [BMI] less than 20 kg/m2, hypoalbuminemia, and/or hypotransferrinemia)
- Obesity (BMI greater than 30 kg/m2)
- Lower than normal hemoglobin levels
Contacts and Locations| Contact: Blake Rasmussen, PhD | 409-747-1619 | blrasmus@utmb.edu |
| Contact: Syed Habeebullah Husaini | 214-729-8893 | shhusain@utmb.edu |
| United States, Texas | |
| Department of Nutrition & Metabolism, University of Texas Medical Branch | Recruiting |
| Galveston, Texas, United States, 77550 | |
| Principal Investigator: Blake Rasmussen, PhD | |
| Principal Investigator: | Blake Rasmussen, PhD | The University of Texas Medical Branch, Galveston |
More Information
No publications provided by The University of Texas, Galveston
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | The University of Texas, Galveston |
| ClinicalTrials.gov Identifier: | NCT00891696 History of Changes |
| Other Study ID Numbers: | 08-306, R01AR049877 |
| Study First Received: | April 29, 2009 |
| Last Updated: | May 31, 2013 |
| Health Authority: | United States: Federal Government |
Keywords provided by The University of Texas, Galveston:
|
Sarcopenia Aging Metabolism Muscle |
mTOR Essential Amino Acids Exercise Rapamycin |
Additional relevant MeSH terms:
|
Sarcopenia Muscular Atrophy Neuromuscular Manifestations Neurologic Manifestations Nervous System Diseases Atrophy Pathological Conditions, Anatomical Signs and Symptoms Nitroprusside Sirolimus Everolimus Vasodilator Agents Cardiovascular Agents |
Therapeutic Uses Pharmacologic Actions Nitric Oxide Donors Molecular Mechanisms of Pharmacological Action Antihypertensive Agents Antibiotics, Antineoplastic Antineoplastic Agents Antifungal Agents Anti-Infective Agents Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Anti-Bacterial Agents |
ClinicalTrials.gov processed this record on June 18, 2013